JP2019514905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514905A5 JP2019514905A5 JP2018555958A JP2018555958A JP2019514905A5 JP 2019514905 A5 JP2019514905 A5 JP 2019514905A5 JP 2018555958 A JP2018555958 A JP 2018555958A JP 2018555958 A JP2018555958 A JP 2018555958A JP 2019514905 A5 JP2019514905 A5 JP 2019514905A5
- Authority
- JP
- Japan
- Prior art keywords
- acrylamidodihydrochloride
- benzimidazol
- diethylamino
- hydroxy
- butyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 102000003964 Histone deacetylase Human genes 0.000 claims 1
- 108090000353 Histone deacetylase Proteins 0.000 claims 1
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 108010021281 angiotensin I (1-7) Proteins 0.000 claims 1
- 229960002756 azacitidine Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 229960003603 decitabine Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330673P | 2016-05-02 | 2016-05-02 | |
| US62/330,673 | 2016-05-02 | ||
| PCT/US2017/030414 WO2017192451A1 (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514905A JP2019514905A (ja) | 2019-06-06 |
| JP2019514905A5 true JP2019514905A5 (enExample) | 2020-05-28 |
Family
ID=60203321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555958A Pending JP2019514905A (ja) | 2016-05-02 | 2017-05-01 | ３−［２−ブチル−１−（２−ジエチルアミノ−エチル）−１ｈ−ベンゾイミダゾール−５−イル］−ｎ−ヒドロキシ−アクリルアミドの多形体形態およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10626092B2 (enExample) |
| EP (2) | EP3452035B1 (enExample) |
| JP (1) | JP2019514905A (enExample) |
| KR (1) | KR20190005904A (enExample) |
| CN (1) | CN109414425A (enExample) |
| AR (1) | AR108257A1 (enExample) |
| AU (1) | AU2017261218A1 (enExample) |
| BR (1) | BR112018072439A2 (enExample) |
| CA (1) | CA3022011A1 (enExample) |
| CL (1) | CL2018003109A1 (enExample) |
| CO (1) | CO2018012941A2 (enExample) |
| EA (1) | EA201892341A1 (enExample) |
| ES (1) | ES2886495T3 (enExample) |
| IL (1) | IL262578A (enExample) |
| MA (1) | MA44880A (enExample) |
| MX (1) | MX382095B (enExample) |
| PH (1) | PH12018502296B1 (enExample) |
| SG (1) | SG11201809471UA (enExample) |
| TW (1) | TW201741286A (enExample) |
| WO (1) | WO2017192451A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018157742A1 (zh) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Sb-939的盐的晶型及其制备方法和用途 |
| EP3728205A1 (en) | 2017-12-19 | 2020-10-28 | Assia Chemical Industries Ltd | Crystalline polymorphs of pracinostat and pracinostat salts |
| WO2019149262A1 (zh) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Sb-939的晶型及其制备方法和用途 |
| US20230159468A1 (en) * | 2020-04-22 | 2023-05-25 | Macfarlan Smith Limited | Novel forms of pracinostat dihydrochloride |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2291749A1 (fr) | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
| JPH07508039A (ja) | 1992-05-20 | 1995-09-07 | メルク エンド カンパニー インコーポレーテッド | ４−アザステロイドのエステル誘導体 |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| IL144214A0 (en) | 1999-01-13 | 2002-05-23 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors |
| EP1206260A4 (en) | 1999-06-30 | 2002-10-30 | Merck & Co Inc | SRC-KINASE INHIBITING COMPOUNDS |
| WO2001000213A1 (en) | 1999-06-30 | 2001-01-04 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| ES2208364T3 (es) | 1999-07-16 | 2004-06-16 | Warner-Lambert Company Llc | Procedimiento para tratar dolor cronico usando inhibidores de mek. |
| PL352835A1 (en) | 1999-07-16 | 2003-09-08 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
| EP1748046A3 (en) | 1999-11-23 | 2007-08-22 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
| NZ514403A (en) | 1999-12-27 | 2002-10-25 | Japan Tobacco Inc | Fused-ring compounds and use thereof as drugs |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1332131A2 (en) | 2000-11-07 | 2003-08-06 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| WO2003000682A1 (en) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| AU2003209060A1 (en) | 2002-02-07 | 2003-09-02 | Axys Pharmaceuticals, Inc. | Assay for acytyltransferase or deacetylase activity |
| KR100984595B1 (ko) | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체 |
| EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
| CA2484261A1 (en) | 2002-04-16 | 2003-10-23 | Teijin Limited | Piperidine derivatives having ccr3 antagonism |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| WO2004078682A2 (en) | 2003-03-05 | 2004-09-16 | Irm Llc | Cyclic compounds and compositions as protein kinase inhibitors |
| US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2005028447A1 (en) | 2003-09-22 | 2005-03-31 | S*Bio Pte Ltd | Benzimidazole derivates: preparation and pharmaceutical applications |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2006101456A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors |
| AU2006201177B2 (en) * | 2005-09-08 | 2012-06-14 | Mei Pharma, Inc. | Heterocyclic compounds |
| TWI393708B (zh) | 2005-09-08 | 2013-04-21 | Mei Pharma Inc | 異羥肟酸脂化合物，其用途及其之合成方法 |
| EP3449923A1 (en) * | 2007-03-07 | 2019-03-06 | MEI Pharma, Inc. | Combination of benzimidazole anti-cancer agent and a second anti-cancer agent |
| HRP20200521T1 (hr) | 2012-10-30 | 2020-08-07 | Mei Pharma, Inc. | Kombinacijske terapije za liječenje kemorezistentnih rakova |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/es unknown
- 2017-05-01 EA EA201892341A patent/EA201892341A1/ru unknown
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/zh active Pending
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 MA MA044880A patent/MA44880A/fr unknown
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/ko not_active Abandoned
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/ja active Pending
- 2017-05-01 ES ES17793075T patent/ES2886495T3/es active Active
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/pt not_active IP Right Cessation
- 2017-05-01 MX MX2018013349A patent/MX382095B/es unknown
- 2017-05-01 US US16/098,435 patent/US10626092B2/en not_active Expired - Fee Related
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/en active Active
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/en not_active Ceased
- 2017-05-01 CA CA3022011A patent/CA3022011A1/en not_active Abandoned
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/en not_active Withdrawn
- 2017-05-02 TW TW106114551A patent/TW201741286A/zh unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296B1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/es unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/es unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned